Finzati - Logo
REGN logo

Regeneron Pharmaceuticals, Inc.

REGN • Biotechnology
$807.48
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$85.78B
Growth
18.8%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 31.4%Positive free cash flow · 39.01Consistent free cash flow · 5/5Reasonable earnings multiple · 17.92Manageable debt level · 0.09
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$807.48
Change0.00%
Shares Out106.80M
Market Cap$85.78B
Enterprise Value$80.49B
52W Range541.00 - 821.11
Beta0.24
P/E19.82
P/S5.52
P/B2.21
P/FCF23.34
EV/Sales5.18

Investment DNA

How strong this company looks for long-term investors

74
out of 100
Business Quality
Margins, moat, returns
85/100
Financial Strength
Debt, cash, stability
95/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
71/100
Why this score▼
Stable or improving margins · 31.4%Positive free cash flow · 39.01Consistent free cash flow · 5/5Reasonable earnings multiple · 17.92Manageable debt level · 0.09Healthy liquidity · 4.13

Analyst view

Analyst sentiment and price target

REGN
Analyst sentiment
Based on 49 analyst votes · 2026-10-20
86/100
Bullish
Bullish
35
Hold
14
Bearish
0
Price Target
2026-07-31
Low
$641.00
Mean
$823.39
Median
$839.50
High
$1000.00

Company Overview

IPO: 4/2/1991
Industry: Biotechnology
P/B i: 2.21
Debt / Equity i: 0.09
Operating Margin: 24.95%
Net Margin: 31.41%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.09
Current Ratio: 4.13
Quick Ratio: 3.39
Status: Strong

Insider Transactions

Recent executive and insider activity

RYAN ARTHUR F
Transaction: 07/02/2026
SELL
Change
-200
Price
$650.15
Filing
07/07/2026
Type
SELL
RYAN ARTHUR F
Transaction: 05/01/2026
SELL
Change
-2
Price
$714.13
Filing
05/04/2026
Type
SELL
RYAN ARTHUR F
Transaction: 04/01/2026
SELL
Change
-40
Price
$779.71
Filing
04/03/2026
Type
SELL